Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Southwest is looking northside as lockdown restrictions ease
When Warren Buffett dumped airline stocks suffering massive losses three weeks ago, he probably overlooked one key aspect about the industry – that no amount of restrictions will kill people’s
Alibaba (BABA) entering a new phase as China emerges from COVID crisis
Alibaba Group Holding Ltd (NYSE: BABA) is striving to regain strength after falling sharply last week, ahead of fourth-quarter earnings. The positive results failed to impress stakeholders as market sentiment
Chinese exodus from US exchanges not an unlikely scenario
The US is now back in the ring with its nemesis China for the second round. This time, the US administration has wasted no time in delivering a massive blow,